The Safety and Effectiveness of Lamivudine Plus Stavudine or Zidovudine in HIV-Infected Patients Who Have Taken Zidovudine

Exclusion Criteria

• •Co-existing Condition:
• •Patients with any of the following symptoms or conditions are excluded:
• •Presence of newly diagnosed AIDS defining opportunistic infection requiring acute therapy at time of enrollment.
• •Intractable diarrhea (\>= 6 loose stools/day for \>= 7 consecutive days).
• •Signs and symptoms of bilateral peripheral neuropathy \>= grade 2 at the time of screening.
• •Inability to tolerate oral medication.
• •Any other clinical conditions that in the opinion of the investigator, would make the patient unsuitable for study or unable to comply with the dosing requirements.
• •Concurrent Medication:
• •Excluded:
• •Therapy with agents with systemic myelosuppressive, neurotoxic pancreatotoxic, hepatotoxic or cytotoxic potential.
• •Therapy with rifampin, rifabutin, terfenadine, astemizole, cisapride, triazolam, midazolam and ketoconazole at any time while on indinavir therapy.
• •Patients with any of the following prior conditions or symptoms are excluded:
• •History of acute or chronic pancreatitis.
• •Prior history of bilateral peripheral neuropathy.
• •Intractable diarrhea (\>= 6 loose stools/day for \>= 7 consecutive days) within 30 days prior to study entry.
• •Prior Medication:
• •Excluded: